| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,162 | 1,200 | 08:16 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11.25 | Modulight Biotherapeutics: $12.2 Million Seed Round Raised To Pioneer Light-Based Therapies For Neurological Disorders | 2 | pulse2.com | ||
| 12.11.25 | Modulight secures $12m to shine precise light on neurological diseases | 1 | Pharmaceutical Technology | ||
| 12.11.25 | Modulight Biotherapeutics Raises $12M in Seed Funding | 1 | FinSMEs | ||
| 24.10.25 | Modulight Oyj: Continued Improvement in Revenue and Profitability | 176 | GlobeNewswire (Europe) | Modulight Corporation | Company Release | October 24, 2025 at 13:00:00 EEST
This release is a summary of Modulight's interim report for January-September 2025. The whole report is attached to this stock... ► Artikel lesen | |
| 22.08.25 | Modulight Oyj: Revenue and profitability improved in line with the strategy | 278 | GlobeNewswire (Europe) | Modulight Corporation | Company Release | August 22, 2025 at 13:00:00 EEST
This release is a summary of Modulight's half-year financial report for January-June 2025. The whole report is attached to... ► Artikel lesen | |
| MODULIGHT Aktie jetzt für 0€ handeln | |||||
| 25.04.25 | Modulight Oyj: Revenue Increased and Profitability Improved | 402 | GlobeNewswire (Europe) | Modulight Corporation | Company Release | April 25, 2025 at 13:00:00 EEST
This release is a summary of Modulight's 1Q25 interim report. The whole report is attached to this stock exchange release as... ► Artikel lesen | |
| 21.02.25 | Modulight Oyj: Strong order intake and cost reductions improved cash flow despite increased R&D investments | 258 | GlobeNewswire (Europe) | Modulight Corporation | Company Release | February 21, 2025 at 13:00:00 EET
This release is a summary of Modulight's financial statements bulletin 2024. The whole report is attached to this stock... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,540 | 0,00 % | Gerüchte & Nervosität bei Eckert&Ziegler: Was steckt dahinter? | ||
| THERMO FISHER | 509,00 | -0,02 % | A Glimpse of Thermo Fisher Scientific's Earnings Potential | ||
| VIVANI MEDICAL | 1,190 | -4,03 % | Vivani Medical, Inc. Announces Closing of Common Stock Offering | ||
| SIEMENS HEALTHINEERS | 42,470 | 0,00 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 51 Euro auf "Neutral" belassen. Europas Medizintechnik-Branche stehe vor einem... ► Artikel lesen | |
| FRESENIUS | 47,650 | 0,00 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
26.01.2026 /... ► Artikel lesen | |
| ENVUE MEDICAL | 2,300 | 0,00 % | ENvue Medical partners with U-Deliver to distribute ENFit syringes | ||
| FRESENIUS MEDICAL CARE | 37,270 | 0,00 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 37,40 Euro auf "Underweight" belassen. Analyst David Adlington nahm am Donnerstagabend in seinem... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 28,800 | 0,00 % | UBS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 53 Euro auf "Neutral" belassen. Europas Medizintechnik-Branche stehe vor einem... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 22,080 | +5,34 % | Alignment Healthcare (ALHC) Drops 12% on Medicare Flat Funding | ||
| BRIGHTSPRING HEALTH SERVICES | 39,550 | +1,28 % | BrightSpring Health stock price target raised to $46 by TD Cowen | ||
| HEARTFLOW | 31,100 | -0,35 % | Heartflow: Wells Fargo startet Coverage mit "Overweight" und Kursziel von 38 $ | ||
| GENEDX | 95,47 | 0,00 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| ADAPTHEALTH | 9,620 | -4,37 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| BETA BIONICS | 14,780 | -1,00 % | Beyond The Numbers: 4 Analysts Discuss Beta Bionics Stock | ||
| PROGYNY | 24,535 | +1,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen |